AN OPEN-LABEL MULTICENTER STUDY OF LOXO-435 (LY3866288) IN ADVANCED SOLID TUMOR MALIGNANCIES WITH FGFR3 ALTERATIONS

Go Back to All Clinical Trials

AN OPEN-LABEL MULTICENTER STUDY OF LOXO-435 (LY3866288) IN ADVANCED SOLID TUMOR MALIGNANCIES WITH FGFR3 ALTERATIONS

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Urothelial Cancer
Age: Between 18 Year(s) - 100 Year(s)
Gender: Male or Female

Other Inclusion Criteria:
1. Between the ages of 40 and 90 years old
2. Tumor must be diagnosed by examining its tissue under a microscope and determined to be a locally advanced or spreading solid tumor (excluding primary brain tumors like gliomas) and show an abnormality in the FGFR3 pathway when tested at a molecular level
3. Estimated life expectancy must be over 12 weeks

You may not be eligible for this study if the following are true:

1. Patients with primary CNS malignancy (i.e., glioma)
2. Known or suspected history of uncontrolled CNS metastases
3. Existing proof of corneal keratopathy (an abnormality of the cornea) or a retinal disorder (a condition affecting the back of the eye) as confirmed by an examination conducted by an eye specialist (ophthalmologist)

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies